Navigation Links
JCI table of contents: March 23, 2009
Date:3/23/2009

ly on hypoxia to promote their own expansion.

In the study, human lung cancer cells were engineered to express the protein myoglobin, which specializes in oxygen transport, storage, and buffering. When these cells were injected into mice, the tumors that developed exhibited no regions of hypoxia, and this was associated with both markedly reduced tumor growth and an inability to metastasize to secondary locations. Further analysis confirmed that the effects were mainly a result of decreased tumor hypoxia, leading the authors to conclude that hypoxia seems to be a key factor driving tumor progression.

In an accompanying commentary, Ulrich Flgel and Chi Dang, highlight the importance of these data and discus other ways in which myoglobin might affect tumor progression.

TITLE: Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis

AUTHOR CONTACT:
Paolo Michieli
University of Turin Medical School, Turin, Italy.
Phone: 39-011-993-3219; Fax: 39-011-993-3225; E-mail: paolo.michieli@ircc.it.

View the PDF of this article at: https://www.the-jci.org/article.php?id=36579

ACCOMPANYING COMMENTARY
TITLE: Myoglobin tames tumor growth and spread

AUTHOR CONTACT:
Ulrich Flgel,
Institut fr Herz- und Kreislaufphysiologie, Heinrich-Heine-Universitt, Dsseldorf, Germany.
Phone: 49-211-8112785; Fax: 49-211-8112672; E-mail: floegel@uni-duesseldorf.de.

Chi Dang
Johns Hopkins Medicine, Baltimore, Maryland, USA.
Phone: (410) 955-2411; Fax: (410) 955-0185; E-mail: cvdang@jhmi.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=38796

'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. JCI table of contents: Sept. 4, 2007
4. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
5. Actavis Launches Carvedilol Tablets in the U.S.
6. Mylan Announces Final FDA Approval for Carvedilol Tablets
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Actavis Launches Amlodipine Tablets in the U.S.
9. Implantable device designed to detect, stop seizures under study at MCG
10. Stevens Health, Technology and Society roundtable: Sept. 19
11. Fruity vegetables and fish reduce asthma and allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... A new analysis of published studies found that ... cancer versus benign disease in regions where infections ... of lung lesions suspicious for cancer could lead ... additional potential complications and mortality. , Histoplasmosis ... that are often concentrated in bird droppings and ...
(Date:9/23/2014)... California, Davis, and Academia Sinica, the preeminent academic ... entered into a collaborative agreement to develop a ... cutting-edge research with opportunities to translate innovative technologies ... The agreement was signed Sept.12 in Taipei by ... Davis and President Chi-Huey Wong of Academia Sinica. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows ... how it can be treated. , A medically retired ... 2006. His platoon sustained multiple attacks resulting in five ... with combat-related PTSD and honorably discharged from the Army. ... had distanced myself from my friends and family,” recalled ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
Breaking Medicine News(10 mins):Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3
... Former Steeler Robin Cole to Appear , , ... be Saturday, August 8, as Experience LEBO and Miller Lite present ... party event, from 8 p.m. to midnight. , , ... to literally party in the street-- Rt. 19/Washington Road closes to vehicular traffic ...
... , FERNDALE, Wash., July 28 Nearly 64 ... vitamin D - a nutrient found to support the immune system, bone strength, ... , manufacturers of a liquid vitamin D3 supplement. , , ... aware that sunscreen, even at SPF15, blocks more than 90 percent of the ...
... , , , ... health care providers and nonprofit health plans, announced today that it ... more than 700 nonprofit agencies nationwide in the second quarter of ... access to high-quality care to uninsured and underserved communities, healthy food ...
... , , LOS ANGELES, ... of next generation digital media protection and intelligence solutions, today ... technology platform to ensure network protection and data security for ... companies, pharmaceutical companies, hospitals, physician practices, and more. In ...
... study by researchers at the Georgetown,s Lombardi Comprehensive Cancer Center ... urine of children with acute lymphoblastic leukemia (ALL), a cancer ... age. The findings are published in the August issue ... caution that these findings should not be seen as cause-and-effect, ...
... , EAST RUTHERFORD, N.J., July 28 Cambrex Corporation (NYSE: CBM ) announced ... closes. , , The Company will host a conference call to discuss the ... Second Quarter 2009 Earnings Conference Call, ... 5, 2009 at 8:30 a.m. Eastern Time, Dial-in: ...
Cached Medicine News:Health News:Mt. Lebanon Comes Alive Saturday, August 8th with ULTRAparty 2Health News:Survey Finds 64% of Americans Unaware Sunscreen Inhibits Vitamin D Production 2Health News:Survey Finds 64% of Americans Unaware Sunscreen Inhibits Vitamin D Production 3Health News:Kaiser Permanente Approves $11 Million in Community Benefit Grants 2Health News:Kaiser Permanente Approves $11 Million in Community Benefit Grants 3Health News:Kaiser Permanente Approves $11 Million in Community Benefit Grants 4Health News:Kaiser Permanente Approves $11 Million in Community Benefit Grants 5Health News:Nexicon Technology to Protect Healthcare Industry 2Health News:Nexicon Technology to Protect Healthcare Industry 3Health News:Nexicon Technology to Protect Healthcare Industry 4Health News:Nexicon Technology to Protect Healthcare Industry 5Health News:Common household pesticides linked to childhood cancer cases in Washington area 2
(Date:9/23/2014)... , Sept. 23, 2014 ... of the "Physician Office Laboratory Markets, 3rd ... This report, Physician Office Laboratory Markets is ... the IVD industry. Physician office laboratories are diverse ... simply perform reimbursable, in-office pregnancy and glucose tests. ...
(Date:9/23/2014)... , Sept. 23, 2014 The Pennsylvania State ... Sat., Sept. 27, as part of National Prescription Drug ... questions asked. Take-Back Day is a national ... Administration (DEA), aimed at encouraging the public to dispose ... prone to abuse and theft. From 10 ...
(Date:9/23/2014)... 23, 2014 Research and Markets ... Vaccine Production Markets" report to their offering. ... and vaccines - including products to treat cancer, diabetes, ... challenges during the final stages of clinical drug testing ... to risk production capital to upscale while anticipating FDA ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3
... Top-line Data to be Released Concurrent with November 9 AHA Data ... ... (Nasdaq: VIAP ), a biotechnology company focused on the development of,compounds ... last patient visit in its Phase 2 acute coronary,syndrome (ACS) study, including ...
... and Efficacy of ORMD 0801, Oral Insulin Capsule, ... on Type 1 ... http://www.oramed.com ), a developer,of oral delivery systems, announced today that it has ... 1 diabetics at the,Hadassah University Medical Center in Jerusalem, Israel., Oramed,s ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial 4Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: